Symvivo Corporation: federal grants and contributions: 3 agreements; $6.0M value; 2 departments; 2 programs.
Assay record ASY-CA-0R877010BH · Cite as: Assay Systems, “Symvivo Corporation: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/symvivo-corporation/
This project will involve further development and characterization of oral bacTRL-based vaccines. This work includes the preclinical development of additional bacTRL-based products including emergent or predicted SARS-CoV-2 variants, as well as the continued evaluation of the lead vaccine candidate in a Phase I clinical trial.
The goal of this project is to develop and clinically evaluate an oral, room temperature stable DNA vaccine candidate for SARS-CoV2. The project will involve the advancement of the bacTRL-Spike COVID-19 vaccine candidate through preclinical development, process development manufacturing scale-up, and first-in-human clinical testing.
Expand biomanufacturing capacity
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.